1. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

   • Pankaj Bhargava
   • John L. Marshall
   • Naiyer A. Rizvi

   Original Article Pages: 95 - 103

2. Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer

   • Koji Takeda
   • Shunichi Negoro
   • Masahiro Fukuoka

   Original Article Pages: 104 - 108

3. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer

   • Ian Olver
   • Margaret Davy
   • Lorraine Webster

   Original Article Pages: 109 - 114

4. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel

   • Srikanth C. Nallani
   • Mary Genter
   • Pankaj B. Desai

   Original Article Pages: 115 - 122

5. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein

   • Cecilia H. Fu
   • Sagrario Martin-Aragon
   • Vassilios I. Avramis

   Original Article Pages: 123 - 133

6. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients

   • Stefanie Reif
   • Dorothea Kingreen
   • Ulrich Jaehde

   Original Article Pages: 134 - 140

7. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines

   • Martin J. Edelman
   • Heather Quam
   • Brian Mullins

   Original Article Pages: 141 - 144

8. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy

   • Omar N. Al Safarjalani
   • Xiao-Jian Zhou
   • Mahmoud H. el Kouni

   Original Article Pages: 145 - 150

9. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

   • Roy S. Herbst
   • Cathleen Lynch
   • Arthur T. Skarin

   Original Article Pages: 151 - 159

10. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice

    • Maria V. Papadopoulou
    • Ming Ji
    • William D. Bloomer

    Original Article Pages: 160 - 168

11. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model

    • Ping Guo
    • Jianguo Ma
    • James M. Gallo

    Original Article Pages: 169 - 176